Related Experiment Video

Updated: Oct 25, 2025

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
09:29

Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model

Published on: March 20, 2020

18.4K

Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions

Fokhrul Hossain1,2, Samarpan Majumder1,2, Justin David3

  • 1Department of Genetics, Louisiana State University Health Sciences Center (LSUHSC), New Orleans, LA 70112, USA.

Cancers
|August 7, 2021
PubMed

Insights

Precision medicine offers new hope for aggressive triple-negative breast cancer (TNBC) treatment, especially for African-American women. Challenges like tumor heterogeneity remain, but subtype-specific therapies show promise for personalized care.

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive, heterogeneous cancer with high recurrence and metastasis rates.
  • TNBC disproportionately affects African-American women.
  • Recent FDA approvals offer targeted therapies for specific TNBC subgroups.

Purpose of the Study:

  • To review the benefits and challenges of precision medicine for TNBC.
  • To discuss the potential of subtype-specific classification in clinical trials.
  • To highlight the ongoing need for adaptive treatment strategies.

Main Methods:

  • Review of current literature on TNBC, precision medicine, and next-generation sequencing.
  • Analysis of recent clinical trial data focusing on TNBC subtype classification.
  • Discussion of challenges including tumor heterogeneity and clonal evolution.

Main Results:

  • Next-generation sequencing advances enable more individualized treatment plans for TNBC.
  • A recent clinical trial targeting TNBC subtypes demonstrates promising results.
  • Tumor heterogeneity and sub-clonal evolution present significant challenges for adaptive precision medicine.

Conclusions:

  • Precision medicine holds significant potential for improving TNBC outcomes.
  • Overcoming tumor heterogeneity is crucial for developing effective adaptive treatment plans.
  • Continued research and clinical trials are essential for advancing precision oncology in TNBC.
Keywords:
TNBC subtypesbreast cancerimmunotherapyprecision medicinetargeted therapytriple-negative breast cancer (TNBC)

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

6.4K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K